INTRODUCTION {#sec1-1}
============

Diabetes mellitus is a major cause of morbidity and mortality worldwide with an increasing prevalence. The WHO estimates a prevalence of 347 million people with diabetes worldwide in 2013 \[[@ref1]\].

There is an emerging trend worldwide for patients with chronic illnesses such as diabetes to use complementary and alternative medicine (CAM) in an attempt to improve the outcomes of their illnesses. Biologic therapies such as herbal remedies are popular \[[@ref2]\], and can broadly be divided into commercialized over-the-counter (OTC) preparations and preparations that are locally sourced and prepared.

Consumers of commercially available herbal products need access to reliable and accessible information to ensure safe and appropriate use. This should preferably be in the form of printed material supplied alongside the product, similar to what's available with conventional medications \[[@ref3]\]. This is particularly important, as it has been shown that the staff knowledge on the products sold in community pharmacies and health food shops is sub-optimal elsewhere \[[@ref4]\]. In addition, there appears to be reluctance on the patient's part in informing about herbal remedies to their respective physicians. One UK study found that a vast majority did not inform their physicians regarding herbal use \[[@ref5]\]. In India, 59.9% of CAM users were not willing to disclose CAM use to their physician \[[@ref6]\]. In Taiwan, 75.4% did not disclose CAM use \[[@ref7]\]. This is of critical importance as many unrecognized interactions may occur between herbal remedies and conventional medicines. Similarly, many patients believe that herbal products are safe and devoid of adverse effects \[[@ref8]\].

Although there is an absence of data for Sri Lanka, these observations may be valid locally as well.

To enable the appropriate and safe use of OTC herbal products, availability of relavant information to the consumer is essential. Particularly information on precautions, adverse events and interactions with conventional medications is critical. Although sale and use of conventional medicine are well regularized globally, herbal medicines (HM) are still largely sold without registration or regulatory supervision.

The European Medicines Agency (EMA) Committee on HM products implemented the development of community herbal monographs for herbal products in 2004. Community herbal monographs collected scientific data on two aspects of a product, namely the well-established use and traditional use. For some plants, the monograph covers the well-established use, as well as traditional use. Traditional use indication gives credentials to a plant based on its long history of traditional use, well-established use indication also implies innovation and research on a plant \[[@ref9]\].

This key directive adopted by the European Parliament in (Directive 2004/24/EC 2004) 2004 enabled the non-prescription use of traditional medicines following assessment of suitability. An important outcome of this was a sharp increase of the HM registrations from 2 in 2005 to 265 in 2012 \[[@ref9]\]. The existence of such a legal framework is critical in registering products based on scientific evidence and well-established safety. However, at consumer level there should be legislation or industry concurrence in making available information to the consumer that enables its safe and effective use.

In most instances, herbal products tend to be registered with their respective regulatory authorities under the "traditional use" category as opposed to the "well-established" category, which is more evidence-based. Although there is some evidence of efficacy for few HM, most lack readily reproducible evidence of efficacy, sufficient to meet regulatory standards \[[@ref3],[@ref9]\]. Further, insufficient research is generated within the use of these medications to make them more likely of obtaining regulatory standards \[[@ref9]\].

Nevertheless, the UK sets a valuable example by requiring products registered as traditional herbal registration (THR) to carry essential safety information in the form of a leaflet \[[@ref10]\]. In 2011, Raynor *et al*. reported that in the UK the majority (93%) of OTC herbal products were unlicensed \[[@ref3]\].

The World Health Organization traditional medicines strategy of 2002 \[[@ref11]\] also highlighted the need for reliable information as a key item to enable the safe and effective use of traditional medicines. In 2003, the WHO addressing the use of HM in developing countries strongly recommended the implementation of national advisory committees and guidelines on herbal remedies. It further emphasized the need of a body for monitoring adverse drug reactions for HM \[[@ref12]\].

At present, there is no legislative framework for registering or regulating the use of OTC herbal products in Sri Lanka.

Essential information that would enable safe use of herbal products includes (1) precautions, (2) interactions, and (3) adverse events such as allergic reactions.

Very few published research studies are available on the safety related issues in dispensing and use of HM.

In a previous publication, we reported a high prevalence of herbal remedy use among Sri Lanka diabetic patients \[[@ref13]\]. These were locally sourced plants that were prepared at home. However, at present, herbal remedies are commercially marketed as capsules, tea bags and syrups, targeting the Sri Lankan diabetic population. There is no published data on the type of products and whether they provide essential information on safe use to consumers.

The aim of this study is to critically evaluate the safety information provided with OTC herbal remedies intended for use among diabetic patients in Sri Lanka and to assess the completeness of the information provided.

MATERIALS AND METHODS {#sec1-2}
=====================

We performed a cross-sectional survey between 20^th^June and 31^st^July 2014, using the printed and internet-based information provided with the OTC herbal products in two major cities in Sri Lanka.

Obtaining the Products {#sec2-1}
----------------------

Samples of commercially available OTC herbal remedies intended for use by diabetic patients fulfilling the inclusion criteria were bought from supermarkets and pharmacies in the cities of Colombo and Kandy, Sri Lanka. The 2 cities were selected on convenience of access. Six supermarkets were visited ensuring that at least one outlet from each chain of supermarkets in these cities was included. The 10 pharmacies were randomly selected from the city centers of both cities, from a total of 96 that dispensed western medicines and OTC herbal products. When products were bought from supermarkets, those fulfilling the inclusion criteria were picked off the shelves. When products were procured from pharmacies, the authors requested for OTC products intended for use by diabetes patients for glycemic control to the pharmacy staff and those that fulfilled the inclusion criteria were selected. Inclusion criteria included labeling stating, use for diabetes, being of herbal origin and availability as an OTC product.

These products were then re-scrutinized to confirm adherence to inclusion criteria once they were purchased. Herbal products that stated diabetes as the sole indication, as well as those that mentioned diabetes as an indication among others were also included.

In Sri Lanka, ayurvedic medicine is a separately registered stream of practice with its own regulatory authority for practice and sale of medication. Pharmacies that dispense ayurvedic medicines are distinct from those dispensing conventional medications. We intentionally did not include products available at the ayurvedic pharmacies, as it was not our intention to scrutinize the safety of herbal products dispensed in these, but rather the safety of those available to the general public as OTC herbal products.

Evaluation Criteria {#sec2-2}
-------------------

The labeling, the package insert and where available websites appearing on the label were scrutinized to gather information about the product. The manufacturer, the active ingredient (s), precautions for use, adverse effects, interactions, indication for use, dose and duration, preparation of the product (tablet, powder, liquid, tea bag, etc.) were recorded as stated by the manufacturer.

We assessed each product to see if they carried information on (1) warning of possible hypoglycemia, (2) Information on adverse events, (3) precautions for use, (4) interactions and, and (5) dose recommendations. A point was awarded for each category of information provided and a score out of 5 was used to assess the completeness of the safety information.

Each category of information (e.g., adverse events) provided for each individual product was then compared against published data to assess if the information provided was complete and accurate.

At present, there is no complete and authoritative reference available to gather information on herbal products. Natural Medicines Comprehensive Database \[[@ref14]\], Stockley's HM interactions \[[@ref15]\], The EMA \[[@ref16]\], the US National Centre for CAM \[[@ref17]\] and online searches on PUBMED using constituent names were used for cross-referencing the information. However, it has to be borne in mind that natural products do not conform to the same stringent scrutiny in relation to adverse event reporting, interactions, etc., as conventional medications and many clinically significant events, therefore, may not be on record at present. We limited our search for adverse events and interactions to those reported in humans.

Accuracy was checked by cross-referencing the stated information against the published data stated above. If all parameters were supplied and were accurate, the product was categorized as complete and accurate.

RESULTS {#sec1-3}
=======

Product Analysis {#sec2-3}
----------------

Eleven products that fulfilled the inclusion criteria were bought from the local supermarkets and pharmacies and analyzed. The manufacturer was mentioned in all the products. Five products contained a single constituent and five more contained more than one. One product failed to mention its constituent(s). Five were marketed as an herbal drink, 3 as herbal tea, 1 as herbal syrup and 2 products were in capsule form. All products stated in the labeling that they were intended for glycemic control. In addition to glucose control, 7 products mentioned additional indications for use; these included diabetic neuropathy, enhancement of memory and cure of circulatory problems.

Package inserts were available in 5/11 (45%) products. Nine products (81.8%) carried telephone numbers or a website for help regarding the product.

Utilizing our scoring system, 9/11 (81.8%) products scored ≤3 on the presence of essential safety information. 2 (18.1%) products scored 4/6.

[Table 1](#T1){ref-type="table"} illustrates the summary of the products and the completeness of the safety information.

###### 

Summary of the products, product information provided and the score depicting completeness of the safety information
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A complete list of the constituents and their frequency in the products are tabulated in [Table 2](#T2){ref-type="table"}.

###### 

Complete list of the constituents and their frequency of inclusion in the products
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Assessment of Safety Information {#sec2-4}
--------------------------------

None of the products had complete and accurate safety information according to our criteria. None specifically stated the risk of hypoglycemia. However, 2 products containing bitter gourd advised patients on regular blood glucose monitoring. Information regarding adverse events was available in only 3 (27%) of the products. Interactions were mentioned in only 1 (8.1%) product. Precautions for use were mentioned by 5 (45%) products. Pregnancy and lactation, heartburn and age \<18 years were some mentioned. The dose was mentioned in all the products, but the duration for use was not mentioned in any. One product contained nutritional information of its contents. The amount of each constituent in weight or volume was mentioned in only 2 products. Details of adverse events and precautions for use as given by the manufacturer are given in [Table 1](#T1){ref-type="table"}.

When the information provided under different categories were assessed for accuracy against published data, none of the products carried information that was accurate and complete. Reported adverse events and interactions of the key constituents of the products are summarized in [Table 3](#T3){ref-type="table"}.

###### 

Reported adverse events and interactions of commonly used selected constituents

![](JIE-4-264-g003)

DISCUSSION {#sec1-4}
==========

Diabetic patients use CAM with the expectation of improving their blood glucose levels \[[@ref2]\]. Patients should be able to expect full disclosure of safety information on purchasing herbal products \[[@ref18]\]. Most patients perceive less adverse events from herbal products than from conventional medicines \[[@ref8]\]. However, most diabetic patients use herbal therapies in conjunction with conventional medications raising the possibility of interactions \[[@ref13]\].

The products we examined, which were specifically marketed for use among diabetic patients contained little or no information on precautions for use, the risk of developing hypoglycemia, interactions or adverse events.

Adverse event information was available in only 3 (27.2%) products. Since most of the products studied contained more than one constituent \[[Table 1](#T1){ref-type="table"}\], the situation is complex in adverse event reporting. Ideally, the manufacturer should mention adverse events for any of the constituents contained in the product. Cinnamon, which was a constituent of two products is known to contain Coumarins \[[@ref19]\]. Coumarins are hepatotoxic and carcinogenic, and Cinnamon already carries a caution from health authorities against prolonged and continued use \[[@ref20]\]. Fenugreek taken orally can cause mild gastrointestinal disturbances like diarrhea, dyspepsia, abdominal bloating and flatulence \[[@ref21]\]. Black seed (*Nigella sativa*) may cause hepatotoxicity in animals, but clinical evidence is lacking \[[@ref22]\]. *In vitro* studies have shown inhibition of platelet aggregation, making bleeding a possibility with black seed oil \[[@ref23]\]. However, no clinical evidence is available at present. Bitter gourd is known to cause abdominal cramps in some \[[@ref24]\]. Dans *et al*. reported the incidence of hypoglycemic coma in children given bitter melon tea \[[@ref25]\].

Some clinically relevant adverse events and interactions of selected herbal constituents are given in [Table 3](#T3){ref-type="table"}. Unfortunately, none of these published adverse events were included in the manufacturer's product information. The absence of a formal method for reporting adverse events, non-recognition of adverse events by patients and clinicians and the small sample sizes of previous studies further confound the situation.

None of the products specifically cautioned the user against the possibility of hypoglycemia. Two products, however, recommended frequent blood glucose monitoring. Most of the individual constituents of each product had published evidence of their potential to lower blood glucose. Cinnamon has the largest pool of evidence to date \[[@ref26]\]. *Selacia reticulata* has evidence for inhibition of intestinal alpha glucosidase and may have clinical significance in reducing postprandial and fasting plasma glucose (FPG) values \[[@ref27]-[@ref29]\]. Evidence of efficacy for bitter melon is similar with some studies showing improvements in FPG and postprandial plasma glucose \[[@ref30],[@ref31]\]. Although a common constituent of many anti-diabetic herbal products, Tanners cassia (*Cassia auriculata*) has not been studied widely in humans. Although it has hypoglycemic effects in experimental rat models \[[@ref32]\] evidence for safety and efficacy in humans is not available.

As the hypoglycemic potential of the commonly used herbal constituents is evidence backed, we believe an appropriate warning on hypoglycemia is essential with these products. Previous studies have demonstrated that CAMs are often used alongside conventional hypoglycemic agents \[[@ref7],[@ref13],[@ref33]\] probably increasing the risk of a serious hypoglycemic event.

Only 1 (8.1%) product had information on interactions. Interactions may occur with the conventional medications or within herbal constituents where more than one constituent is present. Only 4 products had a single constituent whereas 6 products contained at least 2 constituents. Tanners Cassia the constituent in 4 of the products studied is known to cause significant elevation of Carbamazepine levels with continued use \[[@ref34]\].

The commonest precautions stated were use during pregnancy and in individuals less than 18 years.

Using the scoring system we devised, 9/11 products (81.8%) had ≤3 items of the essential items of safety information. Only 2 products (18.1%) had 4 items of information, and none had complete and accurate information.

Raynor *et al.*, studying 68 preparations of 5 commonly purchased OTC herbal products in the UK found that three-quarters of these preparations contained no safety information and only 3 preparations had complete information \[[@ref3]\]. Two-thirds of the products failed to mention interactions.

A study performed in Canada revealed that consumers expect pharmacy staff to be knowledgeable about herbal products \[[@ref35]\]. However, others have recognized that pharmacists where herbal remedies are commonly sold lack knowledge regarding herbal products. There is also evidence that most consumers need help from the pharmacy staff to select a suitable herbal product \[[@ref3]\]. Therefore, the presence of crucial product information is essential to ensure safe dispensing and use.

Most of the databases or texts cited as references \[[@ref14]-[@ref17]\] contained little or no information on the types of herbal products available in the Sri Lankan market. This study provides the evidence supporting to strengthen the regulation of HM locally. The need for developing a sound database, establishing regulatory authority for products that target a specific population of patients should, therefore, take priority considering the number of individuals who consume these products. In Sri Lanka, complementary remedies were used by 76% \[[@ref13]\], in India by 67% \[[@ref36]\] and in Malaysia by 48% \[[@ref2]\] of diabetes patients. In the western countries the prevalence of use varied between 30% and 57% \[[@ref37]\]. In Sri Lanka, all the patients studied continued to use their conventional medications together with herbal use.

The implementation of the "Directive 2004/24/EC" - So called, "traditional HM products directive" resulted in most member countries accepting it with a sharp increase in the registration of herbal products from 2 in 2005 to 265 in 2012 \[[@ref9]\].

There seems to be a welcome trend globally toward uniform registration and safe use of traditional herbal remedies. In Brazil, proposed legislation seeks to separate HM into two categories: HM and traditional herbal product. In 2004, the UK created the new category of THR with a 7-year grace period for all the herbal remedies to be registered under this scheme. This scheme required the consumer to be presented with a leaflet similar to that found on conventional registered products \[[@ref10]\] detailing product information that would enable safe use. A similar strategy needs to be adopted by Sri Lanka if safe practice of herbal therapies were to be implemented.

European directive of 2004 allows a non-EU product to be registered if an HM has been in use for a minimum period of 15-year in the EU. Alternately, generating scientific evidence favoring a product may be used to obtain registration \[[@ref38]\]. Creation of herbal product monographs in the EU has largely simplified the registration of products enabling them to be registered under "well-established use" or traditional use. A similar method of product registration can be utilized in Sri Lanka for products with long-standing history of traditional use, thereby simplifying the process of registration through which legislation can be implemented to promote safe use. In the United Kingdom where herbal medications needed to be registered as THR, 85% of the expected safety information was found to be included within the product \[[@ref3]\]. While these legislative measures would regularize registration, sale, and consumer issues to a large extent, still there would be natural remedies that would not fall within the purview of licensed or regulated products such as garlic, which have been traditionally called food supplements \[[@ref3]\].

Strengths and Limitations {#sec2-5}
-------------------------

The strength of this study is that it opens up a new field of research regarding the provision of safety information together with herbal products. Limitations include the limited number of herbal products available to us through supermarkets and pharmacies allowing only 11 products to be analyzed. Although there is no data on the purchasing patterns of this community with regard to herbal products, we believe our mode of sampling reflects the pattern of the community studied.

CONCLUSION {#sec1-5}
==========

There is a definite deficiency in providing key safety information of the products we studied. At present, Sri Lanka lacks a sound system for OTC herbal product registration and regulation. Since the use of these medications in Sri Lanka is common, it is essential that legislation be enacted to make essential safety information be available in printed form and to set up a regulatory body for product registration and monitoring. Education of the public and conventional medical practitioners may also enable safe use of OTC herbal products.
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